The first China-Global Healthcare Investment & Partnership Summit (CHIPS) will be held in Hengqin from October 29 to 31. It aims to provide a platform for global pharmaceutical companies, investment institutions and industry buyers to identify and access Chinese innovative drug and medical device projects. The summit will be held annually in Hengqin.

Over the past year or two, out-licensing of Chinese innovative drugs has continued to gain momentum, drawing global pharmaceutical companies toward China as a source of pipeline assets. 

In 2025, China's share of global out-licensing value for innovative drugs reached about 49 percent, with 157 deals totaling a potential 135.655 billion USD. In the first half of 2026, 81 related deals were recorded, with a potential total value of around 110 billion USD. 

CHIPS is intended to provide a platform for these transactions and demand, connecting projects, capital, industry buyers, and global resources in an efficient, structured way.

Hengqin was chosen as the venue for its industrial base and policy support in the biopharmaceutical industry. Hengqin is home to nearly 400 biopharmaceutical and health enterprises. 

The University of Macau and the Macau University of Science and Technology have established four State Key Laboratory branches in Hengqin and jointly built nearly 20 laboratories with enterprises. 

Macao’s first cross-border contract-manufactured drug has also been produced in Hengqin and released for sale in Macao. Hengqin is also driving industrial development in modern finance, scientific and technological innovation, and healthcare, offering fertile ground for future cooperation.